Might the EPO’s Enlarged Board of Appeal step into the CRISPR patent battle and reconsider the “all applicants” approach?

Jakob Wested, Timo Minssen, Esther Van Zimmeren

    Abstract

    The Broad Institute is facing a formidable task in defending the revoked CRISPR patent claims in their pending appeal at the EPO. Ultimately, some of the issues might still be referred to the Enlarged Board of Appeal. However, this might require a significant amount of legal and rhetorical agility.
    OriginalsprogEngelsk
    Publikationsdatojul. 2018
    UdgiverHarvard Law School's Bill of Health blog
    StatusUdgivet - jul. 2018

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Might the EPO’s Enlarged Board of Appeal step into the CRISPR patent battle and reconsider the “all applicants” approach?'. Sammen danner de et unikt fingeraftryk.

    Citationsformater